Allarity Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Allarity Therapeutics, Inc. (ALLR) reported Net Income (Loss) Available to Common Stockholders, Basic of -$11.23 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-03-30
- Allarity Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$3.37M.
- Allarity Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$2.81M.
- Allarity Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$2.32M.
- Allarity Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$2.73M.
- Allarity Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$11.23M.
- Allarity Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$25.15M.
- Allarity Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$20.42M.
- Allarity Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$21.05M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | -$3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$6.18M derived: sum of 2 quarters · filed 2026-03-30 | -$8.50M derived: sum of 3 quarters · filed 2026-03-30 | -$11.23M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | -$2.81M 10-Q · filed 2025-11-14 | -$5.13M derived: sum of 2 quarters · filed 2025-11-14 | -$7.86M 10-Q · filed 2025-11-14 | -$15.31M derived: sum of 4 quarters · filed 2026-03-30 | ||
| 2025-06-30 | -$2.32M 10-Q · filed 2025-08-15 | -$5.05M 10-Q · filed 2025-08-15 | -$12.51M derived: sum of 3 quarters · filed 2026-03-30 | -$24.66M derived: sum of 4 quarters · filed 2026-03-30 | ||
| 2025-03-31 | -$2.73M 10-Q · filed 2025-05-09 | -$10.19M derived: sum of 2 quarters · filed 2026-03-30 | -$22.34M derived: sum of 3 quarters · filed 2026-03-30 | -$24.01M derived: sum of 4 quarters · filed 2026-03-30 | ||
| 2024-12-31 | -$7.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$19.61M derived: sum of 2 quarters · filed 2026-03-30 | -$21.27M derived: sum of 3 quarters · filed 2026-03-30 | -$25.15M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | -$12.15M 10-Q · filed 2025-11-14 | -$13.82M derived: sum of 2 quarters · filed 2025-11-14 | -$17.70M 10-Q · filed 2025-11-14 | -$19.42M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | -$1.67M 10-Q · filed 2025-08-15 | -$5.55M 10-Q · filed 2025-08-15 | -$7.27M derived: sum of 3 quarters · filed 2025-08-15 | -$12.82M derived: sum of 4 quarters · filed 2025-08-15 | ||
| 2024-03-31 | -$3.88M 10-Q · filed 2025-05-09 | -$5.60M derived: sum of 2 quarters · filed 2025-05-09 | -$11.15M derived: sum of 3 quarters · filed 2025-05-09 | -$20.94M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | -$1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$7.27M derived: sum of 2 quarters · filed 2025-03-31 | -$17.06M derived: sum of 3 quarters · filed 2025-03-31 | -$20.42M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$5.55M 10-Q · filed 2024-11-14 | -$15.34M derived: sum of 2 quarters · filed 2024-11-14 | -$18.69M 10-Q · filed 2024-11-14 | -$21.80M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$9.79M 10-Q · filed 2024-08-05 | -$13.14M 10-Q · filed 2024-08-05 | -$16.24M derived: sum of 3 quarters · filed 2024-08-05 | -$22.93M derived: sum of 4 quarters · filed 2024-08-05 | ||
| 2023-03-31 | -$3.36M 10-Q · filed 2024-05-14 | -$6.46M derived: sum of 2 quarters · filed 2024-05-14 | -$13.14M derived: sum of 3 quarters · filed 2024-05-14 | -$19.62M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | -$3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$9.79M derived: sum of 2 quarters · filed 2024-03-08 | -$16.27M derived: sum of 3 quarters · filed 2024-03-08 | -$21.05M 10-K · filed 2024-03-08 | -$16.06M 10-K · filed 2023-03-13 | |
| 2022-09-30 | -$6.68M 10-Q · filed 2023-11-14 | -$13.16M derived: sum of 2 quarters · filed 2023-11-14 | -$17.95M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$6.48M 10-Q · filed 2023-08-14 | -$11.27M 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | -$4.65M 10-Q · filed 2023-05-11 | -$3.08M 10-Q · filed 2022-05-27 | ||||
| 2021-12-31 | -$26.65M 10-K · filed 2023-03-13 | |||||
| 2021-09-30 | -$1.35M 10-Q/A · filed 2022-05-17 | $1.67M 10-Q · filed 2021-11-23 | -$6.75M derived: sum of 2 quarters · filed 2022-05-17 | -$9.83M derived: sum of 3 quarters · filed 2022-05-27 | ||
| 2021-06-30 | -$5.40M 10-Q/A · filed 2022-05-17 | -$4.69M 10-Q · filed 2021-11-23 | -$8.48M derived: sum of 2 quarters · filed 2022-05-27 | |||
| 2021-03-31 | -$3.08M 10-Q · filed 2022-05-27 | -$2.96M 10-Q · filed 2021-11-23 | ||||
| 2020-12-31 | -$6.62M 10-K · filed 2022-05-17 | |||||
| 2020-09-30 | -$1.50M 10-Q/A · filed 2022-05-17 | -$960.00K 10-Q · filed 2021-11-23 | -$3.57M derived: sum of 2 quarters · filed 2022-05-17 | -$4.95M derived: sum of 3 quarters · filed 2022-05-17 | ||
| 2020-06-30 | -$2.07M 10-Q/A · filed 2022-05-17 | -$1.96M 10-Q · filed 2021-11-23 | -$3.46M derived: sum of 2 quarters · filed 2022-05-17 | |||
| 2020-03-31 | -$1.39M 10-Q/A · filed 2022-05-17 | -$975.00K 10-Q · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |